Contact
searchSearch
HMP Global
Login
News
Low-Dose CT Screening Reduces Lung Cancer Mortality in a Non–Risk-Based Population
03/26/2026
Emily Estrada
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective...
03/26/2026
Oncology
News
Immune Checkpoint Inhibitor Timing Does Not Impact Survival Outcomes in Patients With Lung Cancer
03/26/2026
Emily Estrada
Results from the i-TIMES study suggest that the timing of immune checkpoint inhibitor administration does not significantly impact overall survival results in advanced lung cancer.
Results from the i-TIMES study suggest that the timing of immune checkpoint inhibitor administration does not significantly impact overall survival results in advanced lung cancer.
Results from the i-TIMES study...
03/26/2026
Oncology
News
Ceralasertib Plus Durvalumab Does Not Improve Outcomes in Advanced Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3...
03/26/2026
Oncology
News
Osimertinib Plus Local Consolidative Therapy Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2...
03/26/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use